靜脈注射人類免疫球蛋白 (IVIG)

用途

• Immune-mediated diseases (IMHA, ITP) - General
• IMHA (refractory to conventional treatment)
• Primary immune-mediated thrombocytopenia (pIMT)
• Refractory erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis, and other cutaneous adverse drug reactions

給藥方式

可能的副作用

• Increased blood pressure
• Local injection site reactions (pain, tenderness)
• Anaphylaxis / Hypersensitivity reactions
• Volume overload (due to colloid-like properties)
• Thrombotic events
• Fever, chills, facial flushing, nausea (human data)
• Renal dysfunction / Acute renal failure (human data)

注意事項與禁忌

• Prior hypersensitivity reactions to human albumin or human blood products
• > **BLACK BOX WARNING (Human Label):** IVIG has been associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death in humans. * **Hypersensitivity:** IVIG contains trace amounts of human albumin, which can trigger severe hypersensitivity or anaphylaxis in dogs, especially upon repeated exposure. * **Infusion Rates:** Adverse reactions are strongly associated with rapid infusion. Must be infused slowly (typically over a 6-12 hour period in dogs). * **Volume Overload:** IVIG has colloid-like properties; use with caution in patients with compromised cardiac or renal function. * **Laboratory Interference:** * *Blood Glucose:* Can cause falsely elevated readings on glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ) based monitors. Use glucose oxidase or other unaffected methods. * *Coombs Test:* Passively transferred antibodies may cause false-positive serological test results.

藥物相互作用

• Live Vaccines: IVIG may interfere with the immune response and efficacy of the vaccine due to passively transferred antibodies.

常見問題